NIDA-1 P50 DA 018185: DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF R

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项人体实验室临床药理学研究，旨在评估静脉注射甲基苯丙胺和利斯的明之间的潜在相互作用，以评估利斯的明治疗甲基苯丙胺依赖的安全性和可能疗效。 主要： ¿ 确定与安慰剂相比，活性药物治疗如何改变 甲基苯丙胺对心血管的影响 ¿ 确定与安慰剂相比，活性药物治疗如何改变 甲基苯丙胺产生的主观和强化效果。 ¿ 确定与安慰剂相比，活性药物治疗如何改变渴望 和寻找毒品的行为。 次要： 确定与安慰剂相比，活性药物治疗如何改变 神经认知功能

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a human laboratory clinical pharmacology study to assess potential interactions between intravenous methamphetamine and rivastigmine, in order to assess the safety and the likely efficacy of rivastigmine for the treatment of methamphetamine dependence. Primary: ¿ To determine how treatment with an active medication, compared to placebo, alters cardiovascular effects produced by Methamphetamine ¿ To determine how treatment with an active medication, compared to placebo, alters subjective and reinforcing effects produced by methamphetamine. ¿ To determine how treatment with an active medication, compared to placebo, alters craving and drug-seeking behavior produced by methamphetamine. Secondary: To determine how treatment with an active medication, compared to placebo, alters neurocognitive functioning.